Pasar al contenido principal

PLATAFORMA DE REACCIONES MULTICOMPONENTE PARA DESCUBRIMIENTO DE REACCIONES Y GENERACION DE NUEVOS COMPUESTOS EN BIOMEDICINA

PID2022-139180OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Multicomponent Reaction-Based Platform Opens New Avenues in Aryl Hydrocarbon Receptor Modulation

  • Nadal Rodríguez, Pau
  • Hartung, Frederick
  • Pedrola, Marina
  • Coomar, Seemon
  • Diaz Moreno, Alejandro
  • Hätälä, Anna M.
  • Rolfes, Katharina M.
  • Sánchez Vera, Ismael
  • Gil, Joan
  • Molins, Elies
  • Viayna, Antonio
  • Hanzl, Alexander
  • Thomä, Nicolas H.
  • Haarmann-Stemmann, Thomas
  • Luque, F. Javier
  • Lavilla, Rodolfo
  • Ghashghaei, Ouldouz
A multidisciplinary platform is presented to address aryl hydrocarbon receptor (AhR) modulation. A rewired Yonemitsu multicomponent reaction with indole 2-carboxaldehydes and nucleophilic species was designed to access a family of 6-substituted indolocarbazoles. The conformational behavior of these compounds was examined to rationalize their axial chirality. In silico docking and molecular simulations highlighted key features implicated in their binding to AhR. Furthermore, the synthesis of linkable derivatives allowed the direct development of conjugated entities. Reporter gene and target gene expression analyses identified these novel structures as potent noncytotoxic activating AhR ligands, that can be extended to bifunctional molecules. The anti-inflammatory properties of these AhR agonists were assessed in interleukin-13 treated keratinocytes. Altogether, the synergistic research in synthetic and computational chemistry integrated with biological studies opens novel avenues toward understanding the biological roles of AhR and the development of targeted therapeutics., We thank Profs. G. Fabriàs, I. Alfonso, Dr. D. Carbajo (IQAC, CSIC Barcelona, Spain), Prof. V. Marchán and Drs. M. A. Molins and A. Gallen (U. Barcelona), Profs. D. Peña and D. Pérez (U. Santiago de Compostela) for useful suggestions and support. We acknowledge the funding from the Ministerio de Ciencia e Innovación-Spain and European Regional Development Fund (EDFR) (PID2022-139180OB-I00, PID2020-117646RB-I00 AEI/10.13039/501100011033, PID2020-120537RB-I00, PID2021-124572OB-C32), Ministerio de Economía y Competitividad-Spain (CEX2021-001202-M), the State Investigation Agency through the Severo Ochoa Programme for Centres of Excellence in R&D (CEX2023-001263-S), Consorci de Serveis Universitaris de Catalunya (CSUC; Molecular Recognition Project) and the Generalitat de Catalunya (2021SGR00357, 2021SGR00671). T.H.-S. acknowledges the support by the German Research Foundation (DFG) FOR 5489 (HA 7346/6-1). P.N.R. thanks Ministerio de Ciencia e Innovación (Spain) for a predoctoral grant. F.H. was supported by the Jürgen Manchot Foundation. N.H.T. acknowledges the support by the European Research Council (ERC) under the European Union’s Horizon 2020 research program (NucEM, No. 884331), the Novartis Research Foundation, the Swiss National Science Foundation (310030_301206 and 310030_214852) and Krebsforschung Schweiz (KFS-5933-08-2023). A.H. is supported by the SNSF Swiss Postdoctoral Fellowship (TMPFP3_224735). The authors acknowledge BioRender.com for assistance with figure creation. For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) license to any accepted manuscript version arising., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2023-001263-S)., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer’s Disease

  • Bagán, Andrea
  • Morales García, José Ángel
  • Escolano, Carmen
Humanity is facing a vast prevalence of neurodegenerative diseases, with Alzheimer’s disease (AD) being the most dominant, without efficacious drugs, and with only a few therapeutic targets identified. In this scenario, we aim to find molecular entities that modulate imidazoline I2 receptors (I2-IRs) that have been pointed out as relevant targets in AD. In this work, we explored structural modifications of well-established I2-IR ligands, giving access to derivatives with an imidazole-linked heterocycle as a common key feature. We report the synthesis, the affinity in human I2-IRs, the brain penetration capabilities, the in silico ADMET studies, and the three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of this new bunch of I2-IR ligands. Selected compounds showed neuroprotective properties and beneficial effects in an in vitro model of Parkinson’s disease, rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine, and showed crucial anti-inflammatory effects in a cellular model of neuroinflammation. After a preliminary pharmacokinetic study, we explored the action of our representative 2-(benzo[b]thiophen-2-yl)-1H-imidazole LSL33 in a mouse model of AD (5xFAD). Oral administration of LSL33 at 2 mg/Kg for 4 weeks ameliorated 5XFAD cognitive impairment and synaptic plasticity, as well as reduced neuroinflammation markers. In summary, this new I2-IR ligand that promoted beneficial effects in a well-established AD mouse model should be considered a promising therapeutic strategy for neurodegeneration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer's Disease

  • Bagán, Andrea
  • Rodriguez-Arévalo, Sergio
  • Taboada-Jara, Teresa
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Brocos Mosquera, Iria|||0000-0002-6471-4892
  • Callado, Luis F.|||0000-0001-9941-012X
  • Morales-García, José A.|||0000-0001-9008-0056
  • Pérez, Belén|||0000-0001-5801-1704
  • Díaz Navarro, Caridad|||0000-0003-1240-0143
  • Fernández-Godino, Rosario
  • Genilloud, Olga
  • Beljkas, Milan
  • Oljacic, Slavica
  • Nikolic, Katarina
  • Escolano, Carmen|||0000-0002-9117-8239
Humanity is facing a vast prevalence of neurodegenerative diseases, with Alzheimer's disease (AD) being the most dominant, without efficacious drugs, and with only a few therapeutic targets identified. In this scenario, we aim to find molecular entities that modulate imidazoline I2 receptors (I2-IRs) that have been pointed out as relevant targets in AD. In this work, we explored structural modifications of well-established I2-IR ligands, giving access to derivatives with an imidazole-linked heterocycle as a common key feature. We report the synthesis, the affinity in human I2-IRs, the brain penetration capabilities, the in silico ADMET studies, and the three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of this new bunch of I2-IR ligands. Selected compounds showed neuroprotective properties and beneficial effects in an in vitro model of Parkinson's disease, rescued the human dopaminergic cell line SH-SY5Y from death after treatment with 6-hydroxydopamine, and showed crucial anti-inflammatory effects in a cellular model of neuroinflammation. After a preliminary pharmacokinetic study, we explored the action of our representative 2-(benzo[b]thiophen-2-yl)-1H-imidazole LSL33 in a mouse model of AD (5xFAD). Oral administration of LSL33 at 2 mg/Kg for 4 weeks ameliorated 5XFAD cognitive impairment and synaptic plasticity, as well as reduced neuroinflammation markers. In summary, this new I2-IR ligand that promoted beneficial effects in a well-established AD mouse model should be considered a promising therapeutic strategy for neurodegeneration.